Compare AstraZeneca plc (AZN) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Sony Group Corp — how do they compare? AstraZeneca plc trades at $157.69 (market cap $245.16B), while Sony Group Corp trades at $23.24 (market cap $138.26B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| AZN | SONY | |
|---|---|---|
Market Cap | $245.16B | $138.26B |
Sector | Health | Technology |
52-Week High | $209.48 | $30.26 |
52-Week Low | $147.06 | $19.32 |
Enterprise Value | $272.43B | $136.18B |
Dividend Yield | 2.02% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Sony's stock trades at $23.54, down 1.18% over 24 hours, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent earnings show mixed quarterly beats, with Q2 2026 EPS of $0.36 exceeding expectations. The company reported strong 2025 fundamentals, including $12.96T revenue and $1.14T net income, though 2026 projections indicate a net loss. Positive sentiment is driven by blockbuster film success, such as Spider-Man: Brand New Day, and a joint venture with TSMC for image sensors, highlighting growth in entertainment and technology segments.
Sony presents a favorable outlook with analyst consensus strongly bullish (68.75% buy ratings) and a potential 29.75% upside. Key opportunities include robust gaming and sensor divisions, but risks involve 2026 profit margin pressures, competitive threats, and execution challenges in new ventures. Investors should weigh solid cash flow and asset base against near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
